Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival

[1]  D. Neuberg,et al.  A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. , 2004, Blood.

[2]  L. Möllgård,et al.  Increased remissions from one course for intermediate‐dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population‐based phase II study , 2003, British journal of haematology.

[3]  M. Fey,et al.  Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Voso,et al.  Acute myeloid leukemia in elderly patients aged over 75 years: experience of a single centre. , 2003, Leukemia & lymphoma.

[5]  F. Appelbaum,et al.  Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. , 2002, Blood.

[6]  R. Stone,et al.  The Difficult Problem of Acute Myeloid Leukemia in the Older Adult , 2002, CA: a cancer journal for clinicians.

[7]  M. Caligiuri,et al.  Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. , 2002, Blood.

[8]  A. Wåhlin,et al.  Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia , 2001, British journal of haematology.

[9]  D. Grimwade,et al.  The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.

[10]  R. Clark,et al.  Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.

[11]  M. Åström,et al.  Adjustment of Incidence Rates after an Estimate of Completeness and Accuracy in Registration of Acute Leukemias in a Swedish Population , 2001, Leukemia & lymphoma.

[12]  E. Estey.  How I treat older patients with AML. , 2000, Blood.

[13]  W. Hiddemann,et al.  Management of acute myeloid leukemia in elderly patients. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Gray,et al.  A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial , 1999, British journal of haematology.

[15]  J. Downing,et al.  Acute myeloid leukemia. , 1999, The New England journal of medicine.

[16]  F. Ferrara,et al.  Acute myeloid leukemia in the elderly: a critical review of therapeutic approaches and appraisal of results of therapy. , 1998, Leukemia & lymphoma.

[17]  M. Slovak,et al.  Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.

[18]  R. Gray,et al.  Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. , 1997, Blood.

[19]  M. Slovak,et al.  Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.

[20]  E. Estey,et al.  Treatment of newly‐diagnosed acute myelogenous leukaemia in patients aged 80 years and above , 1996, British journal of haematology.

[21]  Stephen L. George,et al.  Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia , 1995 .

[22]  C. Tangen,et al.  A Southwest Oncology Group study , 1993 .

[23]  W. Hiddemann,et al.  High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison. , 1993, Leukemia & lymphoma.

[24]  W. Hiddemann,et al.  High-dose versus intermediate-dose cytarabine combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age-adjusted randomized comparison. , 1991, Seminars in hematology.

[25]  B. Löwenberg,et al.  On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.